Skip to main content

Advertisement

Log in

Multicentric Castleman’s disease as a cause for unclear febrile episodes in a 55-year-old HIV-infected man

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Our case illustrates the difficulties involved in diagnosing multicentric Castleman’s disease (MCD) in a human immunodeficiency virus-infected man with febrile episodes and malaise. In the absence of well-established treatment protocols, we have chosen a new treatment algorithm with rituximab, etoposide, and valganciclovir, which led to the remission of clinical symptoms. Yet, we advocate focused exploration for MCD in immunosuppressed patients with unclear febrile episodes, as recent advances in treatment are promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: case no. 40231. N Engl J Med. 1954;250:1001–5.

    Article  PubMed  CAS  Google Scholar 

  2. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4:16–21.

    Article  PubMed  Google Scholar 

  3. Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43:698–704 (Review).

    Article  PubMed  Google Scholar 

  4. Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10:25–35.

    PubMed  Google Scholar 

  5. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96:2069–73.

    PubMed  CAS  Google Scholar 

  6. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20:775–9.

    Article  PubMed  CAS  Google Scholar 

  7. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008;198:23–30.

    Article  PubMed  CAS  Google Scholar 

  8. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25:3350–6.

    Article  PubMed  Google Scholar 

  9. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol. 2011;29:2481–6.

    Article  PubMed  Google Scholar 

  10. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman’s disease with oral etoposide. Am J Hematol. 2001;66:148–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Fehr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lederer, H., Achermann, Y., Tinguely, M. et al. Multicentric Castleman’s disease as a cause for unclear febrile episodes in a 55-year-old HIV-infected man. Infection 40, 203–205 (2012). https://doi.org/10.1007/s15010-011-0174-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-011-0174-9

Keywords

Navigation